Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Seattle researchers map critical molecules that regulate inflammation during flu infection

The influenza virus' ability to mutate quickly has produced new, emerging strains that make drug discovery more critical than ever. For the first time, researchers at Seattle BioMed, along with collaborators at the University of California, San Diego School of Medicine, St. Jude Children's Research Hospital and the University of Washington, have mapped how critical molecules regulate both the induction and resolution of inflammation during flu infection.

6 Jul 2013

Liverpool School of Tropical Medicine receives US$ 10 million to continue research against human filariasis

Liverpool School of Tropical Medicine (LSTM) has received US$ 10 million from the Bill & Melinda Gates Foundation to continue their breakthrough drug discovery and development research against human filariasis - parasitic worm infections which cause river blindness and elephantiasis, some of the world’s most debilitating diseases affecting up to 150 million people in 83 countries throughout the tropics.

1 Jul 2013

University of Manchester, F2G to develop new antifungal drug for fungal infections

F2G Ltd and The University of Manchester Announce a new €6.1million project to develop new antifungal agents to treat resistant fungal infections.

26 Jun 2013

Seattle Genetics collaborates with Bayer HealthCare for new antibody-drug conjugate

Seattle Genetics, Inc. today announced that it has entered into a new antibody-drug conjugate (ADC) collaboration with Bayer HealthCare (Bayer). Under the latest relationship, Bayer will pay upfront and option exercise fees of up to $20 million for worldwide rights to utilize Seattle Genetics' auristatin-based ADC technology with antibodies to several oncology targets.

25 Jun 2013

Newly developed palm-sized microarray platform could enable faster, more efficient drug discovery

A new palm-sized microarray that holds 1,200 individual cultures of fungi or bacteria could enable faster, more efficient drug discovery, according to a study published in mBio-, the online open-access journal of the American Society for Microbiology.

25 Jun 2013

UT candidate wins AHA fellowship to support research in cardiovascular, stroke discoveries

University of Texas at San Antonio biomedical engineering Ph.D. candidate Anand Srinivasan has been awarded a $25,000, one-year doctoral fellowship from the American Heart Association (AHA).

20 Jun 2013

Moffitt Cancer Center, Advinus Therapeutics form strategic partnership

Moffitt Cancer Center announced a strategic partnership with Advinus Therapeutics to advance its discoveries to the clinics. Two promising targeted cancer therapies (Rb:Raf-1 disruptor and ROCK inhibitor) developed by Moffitt scientists are selected as the first set.

18 Jun 2013

NGM, MedImmune partner to develop novel therapeutics for treatment of diabetes and obesity

NGM Biopharmaceuticals, Inc. and MedImmune, the global biologics research and development arm of AstraZeneca, announced today that they have entered into an exclusive agreement to discover, develop and commercialize novel therapeutics from NGM's enteroendocrine cell program for the treatment of type 2 diabetes and obesity.

17 Jun 2013

Drug Innovation Ventures provides development and commercialization solutions for traditional academic drug discovery

Emory University today announced an innovative new public-private drug development enterprise that will transition scientific discoveries more rapidly and efficiently from university laboratories into the marketplace. The new venture is expected to provide global solutions to address worldwide drug development and commercialization needs.

15 Jun 2013

PRISM Pharma announces closing of $15 million Series C financing

PRISM Pharma Co., Ltd., a drug discovery company focused on developing small molecule technologies that modulate protein-protein interactions, today announced the close of an approximately $15 million (approximately ¥1.4 billion) Series C financing.

13 Jun 2013

Inflection Biosciences signs license agreement with CNIO to develop kinase inhibitors for cancer treatment

Inflection Biosciences Ltd, a private company focused on the development of targeted small molecule treatments for cancer, today announced that it has entered into a license agreement with the Spanish National Cancer Research Centre (CNIO) for the exclusive, worldwide rights to develop and commercialise several novel kinase inhibitors for the treatment of cancer.

6 Jun 2013

Research: RG3039 drug can extend survival, improve function in spinal muscular atrophy mouse models

In a new publication that appears in Human Molecular Genetics, the laboratory of Christine DiDonato, PhD reports on their pharmacological characterization of the drug RG3039, demonstrating that it can extend survival and improve function in two spinal muscular atrophy (SMA) mouse models.

5 Jun 2013

Alios begins oral dosing of ALS-8176 in Phase 1 clinical trial for RSV infection

Alios BioPharma, Inc. today announced that it has begun oral dosing of ALS-8176 in a Phase 1 clinical trial. ALS-8176 is a structurally novel, anti-respiratory syncytial virus (RSV) nucleoside analog that is being developed for the treatment of acute RSV infection.

31 May 2013

New avatar system could provide quick and effective therapy for schizophrenia

An avatar system that enables people with schizophrenia to control the voice of their hallucinations is being developed by researchers at UCL with support from the Wellcome Trust.

31 May 2013

Queen's University Belfast scientists awarded research grants to tackle tropical diseases

Queen's University Belfast has been announced as a Grand Challenges Explorations winner, an initiative founded by the Bill & Melinda Gates Foundation. Scientists at the University's Institute for Global Food Security have been awarded grants to pursue two Innovative global health and development research projects aimed at tackling tropical diseases.

31 May 2013

Research discovery may lead to development of new therapies for neurological disorders

For several years, the pharmaceutical industry has tried to develop drugs that target a specific neurotransmitter receptor in the brain, the NMDA receptor. This receptor is present on almost every neuron in the human brain and is involved in learning and memory. NMDA receptors also have been implicated in several neurological and psychiatric conditions such as Alzheimer's disease, Parkinson's disease, schizophrenia and depression.

29 May 2013

FAPESP funds $680 million to support 17 RIDCs

The Brazilian funding agency for scientific and technological research S-o Paulo Research Foundation, FAPESP, based in the state of S-o Paulo, announced an investment estimated in US$ 680 million to support 17 Research, Innovation and Dissemination Centers for a period of up to eleven years, subject to continuation reviews on years 2, 4 and 7.

22 May 2013

A*STAR, Cytos Biotechnology provide update on Phase 1 clinical trial of H1N1 influenza vaccine

Singapore's Agency for Science, Technology and Research and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their H1N1 influenza vaccine candidate based on Cytos' proprietary bacteriophage Qbeta virus-like particle technology.

17 May 2013

Research findings may pave way to new treatment for Alzheimer's disease in humans

A drug developed by scientists at the Salk Institute for Biological Studies, known as J147, reverses memory deficits and slows Alzheimer's disease in aged mice following short-term treatment.

14 May 2013

Mathematical model with prognostic factors predicts treatment effect with bevacizumab in colorectal cancer patients

Certara-, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, announced that its Pharsight Consulting Services has developed a mathematical model of tumor growth inhibition, which when combined with baseline prognostic factors, predicts treatment effect with bevacizumab for patients with metastatic colorectal cancer.

9 May 2013

Drug Discovery News and Research

Further Reading

Seattle researchers map critical molecules that regulate inflammation during flu infection

Liverpool School of Tropical Medicine receives US$ 10 million to continue research against human filariasis

University of Manchester, F2G to develop new antifungal drug for fungal infections

Seattle Genetics collaborates with Bayer HealthCare for new antibody-drug conjugate

Newly developed palm-sized microarray platform could enable faster, more efficient drug discovery

UT candidate wins AHA fellowship to support research in cardiovascular, stroke discoveries

Moffitt Cancer Center, Advinus Therapeutics form strategic partnership

NGM, MedImmune partner to develop novel therapeutics for treatment of diabetes and obesity

Drug Innovation Ventures provides development and commercialization solutions for traditional academic drug discovery

PRISM Pharma announces closing of $15 million Series C financing

Inflection Biosciences signs license agreement with CNIO to develop kinase inhibitors for cancer treatment

Research: RG3039 drug can extend survival, improve function in spinal muscular atrophy mouse models

Alios begins oral dosing of ALS-8176 in Phase 1 clinical trial for RSV infection

New avatar system could provide quick and effective therapy for schizophrenia

Queen's University Belfast scientists awarded research grants to tackle tropical diseases

Research discovery may lead to development of new therapies for neurological disorders

FAPESP funds $680 million to support 17 RIDCs

A*STAR, Cytos Biotechnology provide update on Phase 1 clinical trial of H1N1 influenza vaccine

Research findings may pave way to new treatment for Alzheimer's disease in humans

Mathematical model with prognostic factors predicts treatment effect with bevacizumab in colorectal cancer patients

Drug Discovery - Second Edition eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News